SecBot SecBot
8-K ·Filed Jun 29, 2026

EBS

Emergent BioSolutions Inc.
BULLISH
Impact 5/10
Horizonweeks Processed4mo ago SEC0001367644-26-000068
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The $52.7M award adds near-term revenue visibility through December 2026. Monitor for additional option exercises or international orders, but the stock may already price in routine government contract flow. No earnings or guidance changes accompany this filing.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.46
T+0 close · Jun 29, 2026 · via day close
Latest settled
−20.09%
T+60 · $6.76
Vs SPY
−24.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $8.46entry
  2. T+1 · 5mo ago −0.95%α −1.72% · $8.38
  3. T+5 · 4mo ago −3.31%α −4.70% · $8.18
  4. T+20 · 4mo ago −14.18%α −13.90% · $7.26
  5. T+60 · 8w ago −20.09%α −24.46% · $6.76
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Emergent BioSolutions received a $52.7 million contract modification from the U.S. government (ASPR) for ACAM2000 vaccine supply under an existing 10-year contract. Deliveries begin June 2026, with diluent lots by December 2026. This is a material but routine government award, providing near-term revenue visibility.

Key Facts

  • Contract modification valued at $52.7 million from ASPR for ACAM2000 vaccine
  • Deliveries of doses and ancillaries to begin June 2026; diluent replacement lots by December 2026
  • Modification exercises Option Year 7 under existing 10-year contract (75A50119C00071)
  • Recent international approvals: Saudi FDA and Singapore HSA expanded ACAM2000 indications for mpox

Financial Impact

$52.7 million contract modification, representing ~12% of current market cap

revenue

Risk Factors

  • Government contract dependency; budget or policy shifts could impact future awards
  • Execution risk on delivery timelines and diluent production
  • ACAM2000 safety profile (boxed warning for myocarditis, pericarditis) limits commercial expansion

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001367644-26-000068
Document: a06292026acammodpr.htm0001367644-26-000068
Document: 0001367644-26-000068-index-headers.html0001367644-26-000068
Document: 0001367644-26-000068-index.html0001367644-26-000068
Document: 0001367644-26-000068.txt0001367644-26-000068

Track record

23 reports on EBS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
  4. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
  5. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
  6. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
  7. Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
  8. Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
  9. Jun 29, 202620w ago 8-K Bullish 5/10 Viewing Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
  10. Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026